Inhibitors of Cysteine Proteases and Methods of Use Thereof (2021)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 63/179,128, filed Apr 23, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,174,231 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | Pardes Biosciences, Inc. | In force | High confidence | ||
| US 11,524,940 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | Pardes Biosciences, Inc. | In force | High confidence | ||
| US 12,145,911 | Inhibitors of Cysteine Proteases and Methods of Use Thereof In force · High confidence | Pardes Biosciences, Inc. | In force | High confidence | ||
| Application 18/789,006 | Inhibitors of Cysteine Proteases and Methods of Use Thereofs Pending Not granted | Pardes Biosciences, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Pardes Biosciences, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.